生脉注射液物质组成、临床前药动学和药效学的研究进展

生脉注射液(Shengmai Injection,SMI)是由红参、麦冬和五味子3味中药组成的中药复方制剂,在临床上除了广泛用于治疗心血管系统疾病外,还用于抗肺病、癌症化疗等的辅助治疗。近年来,SMI的临床前基础研究日渐广泛,主要包括SMI的化学成分、体内过程和作用机制等,为揭示该方的药效物质基础提供了一定的科学依据。综述了该方的物质组成、临床前药动学和药效学研究,以期为SMI的质量控制、产品二次开发和临床合理应用提供参考。

Research progress on material composition, pre-clinical pharmacokinetic, and pharmacodynamic studies of Shengmai Injection

Shengmai Injection (SMI), is a traditional Chinese medicine (TCM) formula injection composed of Panax ginseng, Ophiopogon japonicas and Schisandra chinensis, which is widely used in clinic for the treatment of cardiovascular diseases as well as protecting against pulmonary disease and add-on therapy to cancer chemotherapy. In recent years, the pre-clinical basic research of SMI was widely performed. The studies, including chemical composition, in vivo process, and action mechanism and so on of SMI, helped to provide scientific foundation for revealing the material basis of formula. In this paper, the studies on material composition, pre-clinical pharmacokinetics and pharmacodynamics of this formula were summarized, so as to provide reference for the quality control, second development and rational clinical application of SMI.